Technical Analysis for AGLE - Aeglea BioTherapeutics, Inc.

Grade Last Price % Change Price Change
C 8.1 1.89% 0.15
AGLE closed up 5.3 percent on Thursday, April 15, 2021, on 70 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical AGLE trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 1.89%
Crossed Above 20 DMA Bullish 1.89%
Crossed Above 50 DMA Bullish 1.89%
Up 3 Days in a Row Strength 1.89%
50 DMA Resistance Bearish 7.28%
Fell Below 50 DMA Bearish 11.72%
MACD Bearish Centerline Cross Bearish 11.72%
50 DMA Support Bullish 5.06%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 5.06%
NR7 Range Contraction 5.06%
Older End-of-Day Signals for AGLE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
20 DMA Support about 2 hours ago
Rose Above Previous Day's High about 3 hours ago
1.5x Volume Pace about 3 hours ago
Down 1% about 3 hours ago
Up 2% about 3 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aeglea BioTherapeutics, Inc. Description

Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. It develops AERase/AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment of hyperargininemia and cancer; and AECase/AEB3103, an engineered and PEGylated human cysteine/cystine degrading enzyme that increases oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies. The company also engages in developing AEMase/AEB2109, an engineered human enzyme that degrades methionine for the treatment of solid tumors; and AEB4104, an engineered human enzyme that degrades homocysteine in the circulation for the treatment of inborn error of metabolism homocystinuria. It has a strategic partnership with KBI Biopharma. Aeglea Biotherapeutics, Inc. was formerly known as Aeglea BioTherapeutics Holdings, LLC. The company was founded in 2013 and is based in Austin, Texas.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acid Solid Tumors Enzymes Metabolism Organic Chemistry Inborn Errors Of Metabolism Oxidative Stress Cystinuria Homocystinuria

Is AGLE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.38
52 Week Low 5.1
Average Volume 170,140
200-Day Moving Average 7.80
50-Day Moving Average 7.68
20-Day Moving Average 7.79
10-Day Moving Average 7.78
Average True Range 0.48
ADX 9.64
+DI 25.38
-DI 22.76
Chandelier Exit (Long, 3 ATRs ) 7.36
Chandelier Exit (Short, 3 ATRs ) 8.48
Upper Bollinger Band 8.59
Lower Bollinger Band 6.99
Percent B (%b) 0.6
BandWidth 20.48
MACD Line -0.03
MACD Signal Line 0.00
MACD Histogram -0.0255
Fundamentals Value
Market Cap 381.1 Million
Num Shares 47.9 Million
EPS -2.30
Price-to-Earnings (P/E) Ratio -3.46
Price-to-Sales 0.00
Price-to-Book 2.95
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.71
Resistance 3 (R3) 8.66 8.35 8.58
Resistance 2 (R2) 8.35 8.16 8.38 8.54
Resistance 1 (R1) 8.15 8.04 8.25 8.20 8.50
Pivot Point 7.85 7.85 7.90 7.87 7.85
Support 1 (S1) 7.65 7.66 7.75 7.70 7.40
Support 2 (S2) 7.34 7.54 7.37 7.36
Support 3 (S3) 7.14 7.34 7.32
Support 4 (S4) 7.19